This company has been acquired
Lumos Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Lumos Pharma has a total shareholder equity of $4.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $17.5M and $12.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$13.52m |
| Equity | US$4.91m |
| Total liabilities | US$12.55m |
| Total assets | US$17.46m |
Recent financial health updates
We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
May 23
We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
Aug 25Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?
Mar 13Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation
Mar 22Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth
Nov 04Recent updates
We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
May 23We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
Aug 25Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?
Mar 13Lumos Pharma announces new buyback program
Aug 16Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation
Mar 22Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth
Nov 04What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?
Dec 09Lumos Pharma (LUMO) Investor Presentation - Slideshow
Nov 17Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 11Financial Position Analysis
Short Term Liabilities: LUMO's short term assets ($17.3M) exceed its short term liabilities ($6.5M).
Long Term Liabilities: LUMO's short term assets ($17.3M) exceed its long term liabilities ($6.0M).
Debt to Equity History and Analysis
Debt Level: LUMO is debt free.
Reducing Debt: LUMO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LUMO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: LUMO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.2% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/13 20:39 |
| End of Day Share Price | 2024/12/11 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lumos Pharma, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Eun Kyung Yang | Jefferies LLC |
| Elemer Piros | Roth MKM |